Kestra Medical plans sale of 7,857 common shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. reports a planned sale of 7,857 shares of common stock through Merrill Lynch on July 30, 2026. These shares relate to a performance stock issuance dated July 17, 2026, granted under an issuer equity compensation plan. Recent sales over the past three months include four transactions of 15,000 common shares each by Brian Webster.
Key Figures
Key Terms
Performance Stock Issuance financial
issuer equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kestra Medical Technologies (KMTS) disclose in this Form 144 filing?
What recent Kestra Medical Technologies (KMTS) stock sales are reported for the past 3 months?
AI-generated analysis. How Rhea-AI works. Not financial advice.